重组Anti-CBL (phospho Y674)抗体[EPR2227] (ab76536)
![Western blot - Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)](https://www.abcam.cn/ps/products/76/ab76536/Images/ab76536-92009-anti-cbl-phospho-y674-antibody-epr2227-western-blot.jpg "Western blot - Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2227] to CBL (phospho Y674)
- Suitable for: Flow Cyt (Intra), WB
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-CBL (phospho Y674)抗体[EPR2227]
参阅全部 CBL 一抗 -
描述
兔单克隆抗体[EPR2227] to CBL (phospho Y674) -
宿主
Rabbit -
经测试应用
适用于: Flow Cyt (Intra), WBmore details
不适用于: IHC-P or IP -
种属反应性
与反应: Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
- Jurkat cell lysate treated with pervanadate. Permeabilized Jurkat cells.
-
常规说明
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
存储溶液
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading... -
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR2227 -
同种型
IgG -
研究领域
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Co-activators/co-repressors
相关产品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab76536于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度；实际最佳的稀释度/浓度应由使用者检定。
| 应用 | Ab评论 | 说明 |
|---|---|---|
| Flow Cyt (Intra) |
1/20.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
| WB |
1/1000. Predicted molecular weight: 100 kDa.
|
| 说明 |
|---|
|
Flow Cyt (Intra)
1/20. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB
1/1000. Predicted molecular weight: 100 kDa. |
应用说明
Is unsuitable for IHC-P or IP.
靶标
-
功能
Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling. -
通路
Protein modification; protein ubiquitination. -
疾病相关
Defects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. -
序列相似性
Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain. -
结构域
The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain. -
翻译后修饰
Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR. -
细胞定位
Cytoplasm. - Information by UniProt
-
数据库链接
- Entrez Gene: 867 Human
- Omim: 165360 Human
- SwissProt: P22681 Human
- Unigene: 504096 Human
-
别名
- 4732447J05Rik antibody
- C CBL antibody
- Cas Br M (murine) ecotropic retroviral transforming sequence antibody
see all
图片
-
Western blot - Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)All lanes : Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536) at 1/1000 dilution
Lane 1 : Jurkat cell
lysate
Lane 2 : Jurkat cell
lysate treated with
pervanadate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/1000 dilution
Predicted band size: 100 kDa
Observed band size: 120 kDa why is the actual band size different from the predicted? -
![Flow Cytometry (Intracellular) - Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)](https://www.abcam.cn/ps/products/76/ab76536/Images/ab76536-92008-anti-cbl-phospho-y674-antibody-epr2227-flow-cytometry.jpg)
Flow Cytometry (Intracellular) - Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)Intracellular flow cytometric analysis of permeabilized Jurkat cells, un-treated (green) or pervanadate treated (red) using ab76536 at a 1/20 dilution, and pervanadate-treated Jurkat cells using the same antibody pre-incubated with phospho-CBL peptide (blue) or non-phospho-CBL peptide (orange).
-
![Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)](https://www.abcam.cn/ps/products/76/ab76536/Images/ab76536-3-benefits-of-recombinant-antibodies.png)
Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536)
数据表及文件
-
SDS download
-
Datasheet download
文献 (2)
ab76536 被引用在 2 文献中.
- Garcia EG et al. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. Leukemia 35:679-690 (2021). PubMed: 32606318
- Bunaciu RP et al. Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment. Oncotarget 9:4134-4149 (2018). PubMed: 29423110